Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT04666090 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04666090
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-23
- Primary completion
- 2022-12-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.